DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/67zshp/linzess) has announced the addition of the "Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering.
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Linzess (linaclotide) is indicated for the treatment of IBS-C in adults. This product was initially discovered by Ironwood Pharmaceuticals, and its development and commercialization were supported by a series of licensing agreements with Forest in the US, Almirall in the EU, and Astellas in Japan. As of November 2014, Linzess was in Phase III of development as a potential treatment for IBS-C in Japan, and is therefore not currently available in this market.
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Linzess, including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Linzess for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Linzess (linaclotide)
7 Appendix
For more information visit http://www.researchandmarkets.com/research/67zshp/linzess.
